Business Context and Reporting Period
This Form 8-K Current Report was filed by Sino-Global Shipping America, Ltd. on November 14, 2018, covering events occurring on November 8, 2018. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of common stock.
Key Financial Metrics
The filing details a capital raise transaction with the following specific metrics:
- Gross Proceeds: $1,000,000.
- Purchase Price: 120% of the average closing price of the Common Stock on the NASDAQ Stock Market over the five consecutive trading days immediately prior to closing.
- Security Type: Restricted shares of common stock (no par value).
- Liquidity/Restrictions: Shares are subject to a one-year restrictive period and cannot be resold without an effective registration statement or valid exemption.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of a Share Purchase Agreement with Mr. Xiangbin Huang, an accredited investor based in the People's Republic of China. Additionally, the Investor has agreed to facilitate an opportunity for the Company to provide pharmaceutical cold chain logistics services in the Chengdu area and throughout China.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of the transaction and the strategic intent to expand into pharmaceutical cold chain logistics in China. The filing notes that the Shares are restricted, creating a liquidity constraint for the Investor for one year. No specific financial guidance or forward-looking projections were included in this report.
Investor Verification Checklist
- Verify the final closing price per share based on the 5-day average prior to the transaction close.
- Confirm the actual closing date of the transaction to determine the exact number of shares issued.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for additional covenants or conditions.
- Assess the feasibility and timeline of the proposed pharmaceutical cold chain logistics services in Chengdu.